Clinical trials · Raleigh–Durham, NC
Multiple myeloma clinical trials in Raleigh–Durham
We’re tracking 43 recruiting multiple myeloma studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Chapel Hill, North CarolinaAges 18 years+ - NCT01137643Recruiting
Sharing blood and tissue samples for blood cancer research
This trial collects tissue, blood, and other body fluid samples from people with blood-related cancers. The goal is to help researchers study these diseases by building a source of samples for future testing.
Chapel Hill, North CarolinaAges 18–120 - NCT03717844Recruiting
Registry for adults with plasma cell disorders
This study is a registry that collects information about adults with plasma cell disorders (conditions involving abnormal antibody-producing cells). It may help researchers understand these diseases better and improve future care by tracking patients over time.
Chapel Hill, North CarolinaAges 18 years+ - NCT06296368Recruiting
A tool to help older adults make cancer care decisions
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
Chapel Hill, North CarolinaAges 60 years+ - NCT05714839RecruitingPhase 1/Phase 2
Belantamab for multiple myeloma that has returned
This trial tests a new drug called belantamab, either alone or combined with other treatments, for people with multiple myeloma that has come back after several prior therapies. It aims to see how safe and effective belantamab is and whether it can help control the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT07053436RecruitingPhase 2
New treatment for high-risk myeloma before transplant
This study tests a new treatment combination for people with high-risk multiple myeloma who are newly diagnosed and healthy enough for a stem cell transplant. The goal is to see if the treatment can improve outcomes compared to standard therapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT02693535RecruitingPhase 2
Match FDA cancer drugs to a tumor gene change
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
Chapel Hill, North CarolinaAges 12 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Chapel Hill, North CarolinaAges 18 years+ - NCT04771572RecruitingPhase 1
Oral drug LP-118 for relapsed blood cancers
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
Chapel Hill, North CarolinaAges 13 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
Chapel Hill, North CarolinaAges 18 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Chapel Hill, North CarolinaAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Chapel Hill, North CarolinaAges 18 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Chapel Hill, North CarolinaAges 18 years+ - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Chapel Hill, North CarolinaAges 19 years+ - NCT06083922RecruitingPhase 2
CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
Chapel Hill, North CarolinaAges 18 years+ - NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma with or without other drugs
This trial tests a new oral drug called surzetoclax, alone or with other myeloma treatments, for people with a specific type of multiple myeloma. It aims to see if the drug is safe and helps control the disease.
Chapel Hill, North CarolinaAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Hillsborough, North CarolinaAges 18 years+ - NCT06375044RecruitingPhase 1
Study of SIM0500 for relapsed or refractory multiple myeloma
This trial tests a new medication, SIM0500, for people whose multiple myeloma has returned or stopped responding to other treatments. It aims to see if the drug is safe and effective for those who have tried all standard options.
Hillsborough, North CarolinaAges 18 years+
Hear when a new Multiple myeloma trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Multiple myeloma trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting multiple myeloma studies listed above.
- University of North Carolina at Chapel Hill · 9 studies
- UNC Lineberger Comprehensive Cancer Center · 3 studies
- GSK Investigational Site
- North Carolina Cancer Hospital
- Research Site
- UNC Children's Hospital
- UNC Health
- University of North Carolina Hospitals - Hillsborough Campus
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting multiple myeloma studies in North Carolina.
Common questions
- Are there multiple myeloma clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 43 recruiting multiple myeloma studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.